(Atezolizumab)Biosimilar Reference Antibody

Atezolizumab is a fully humanized, engineered monoclonal antibody of the IgG1 isotype, designed as an immune checkpoint inhibitor. It specifically targets programmed death-ligand 1 (PD-L1), blocking its interaction with the PD-1 and B7.1 (CD80) receptors on immune cells. This blockade releases inhibitory signals on T cells, thereby reinvigorating the anti-tumor immune response. Developed by Genentech/Roche, it is approved for the treatment of multiple advanced cancers, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), hepatocellular carcinoma (HCC), and urothelial carcinoma, often in combination with chemotherapy or other agents.